Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222732 | 0.78 | ALDH1A1 (0.30) | ALDH1A1HSD17B10 | |
| SCHEMBL7131658 | 0.78 | — | — | |
| SCHEMBL6051921 | 0.76 | ALDH1A1 (0.41) | MAOBMAOARAB9AMEN1KMT2A | |
| SCHEMBL1377576 | 0.75 | MAOB (0.48) | MAOBMAOARAB9AMEN1KMT2A | |
| SCHEMBL1136612 | 0.75 | MAOB (0.48) | MAOBMAOARAB9AMEN1KMT2A | |
| SCHEMBL61411 | 0.74 | MAOB (0.71) | MAOBMAOARAB9AMEN1KMT2A | |
| SCHEMBL12854020 | 0.74 | MAOB (0.71) | MAOBMAOARAB9AMEN1KMT2A | |
| SCHEMBL8956841 | 0.74 | ENPP1 (0.34) | MAOBRAB9AMEN1KMT2AMETAP2 | |
| SCHEMBL3230996 | 0.74 | DYRK1A (0.33) | BRD4 | |
| SCHEMBL3215613 | 0.73 | KIT (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269748-A1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-03 | — | — | US | claimed |
| CN-101291582-A | Novel imidazo based heterocycles | ABBOTT LAB (US) | 2008-10-22 | — | — | CN | claimed |
| EP-1926719-A2 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-04 | — | — | EP | claimed |
| WO-2007031440-A2 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | WO | claimed |
| CN-1658873-A | New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-24 | — | — | CN | claimed |
| CN-1658834-A | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-24 | — | — | CN | claimed |
| CN-118184702-A | Antiviral prodrugs and uses thereof | 上海柯君医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-3271015-A1 | NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC OR COSMETIC TREATMENT OF EXCESS BODY FAT | OGEDA S.A. (BE) | 2018-01-24 | — | — | EP | disclosed |
| EP-1926719-B1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016146712-A1 | NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC OR COSMETIC TREATMENT OF EXCESS BODY FAT | EUROSCREEN SA (BE) | 2016-09-22 | — | — | WO | disclosed |
| US-9388175-B2 | 2-aniline-4-aryl substituted thiazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-07-12 | — | — | US | disclosed |
| EP-2655344-A1 | NOVEL PHENAZINE DERIVATIVES AND THEIR USE | Université Catholique de Louvain (BE) | 2013-10-30 | — | — | EP | disclosed |
| CN-103271906-A | Use of spiro-oxindole compounds as therapeutic agents | XENON PHARMACEUTICALS INC | 2013-09-04 | — | — | CN | disclosed |
| CN-101454004-A | Pyridone sulfonamides and pyridone sulfamides as mek inhibitors | ARDEA BIOSCIENCES INC (US) | 2009-06-10 | — | — | CN | disclosed |
| CN-101355968-A | Compositions and methods for treating thrombocytopenia | ASTELLAS PHARMA INC (JP) | 2009-01-28 | — | — | CN | disclosed |
| CN-101291582-A | Novel imidazo based heterocycles | ABBOTT LAB (US) | 2008-10-22 | — | — | CN | disclosed |
| EP-1926719-A2 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031440-A2 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | WO | disclosed |
| CN-1658834-A | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658873-A | New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269748-A1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | CHRNA4, CHRNA5, CHRNA7 | MAOB 614/4885MAOA 451/4885RAB9A 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.